Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Paclitaxel].

Y Omuro1, T Sasaki

  • 1Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 30, 2001
PubMed
Summary

The optimal dose for paclitaxel is 175 mg/m2 over 3 hours. Weekly administration shows promise for dose-dense therapy with minimal myelosuppression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-translational processing of rac p21s is important both for their interaction with the GDP/GTP exchange proteins and for their activation of NADPH oxidase.

The Journal of biological chemistry·1992
Same author

Nodular scleroderma in systemic sclerosis under D-penicillamine therapy.

The Journal of dermatology·1992
Same author

Isolation and identification of a cytotoxic principle from Chrysosplenium grayanum Maxim. (Saxifragaceae) and its antitumor activities.

Chemical & pharmaceutical bulletin·1992
Same author

Shortening of N1 and P3 latencies in event-related potentials observed coincidentally with clinical improvement during nootropic medication in a demented patient: specific effect of nicergoline.

The Japanese journal of psychiatry and neurology·1992
Same author

Effect of short-term fasting treatment on liver and renal function.

The Kitasato archives of experimental medicine·1992
Same author

Immunocytochemical localization of cathepsins B and G in odontoclasts of human deciduous teeth.

Journal of dental research·1992

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Context:

  • The optimal dosing and administration schedule for paclitaxel, a widely used chemotherapy agent, remains under investigation.
  • Existing clinical trials have not established a definitive dose-response relationship for single-agent paclitaxel.
  • Comparative studies on infusion durations (3h, 24h, 96h) have not identified a superior schedule.

Purpose:

  • To review current clinical evidence regarding the optimal dose and schedule of single-agent paclitaxel.
  • To evaluate the efficacy and tolerability of different paclitaxel administration regimens.

Summary:

  • Current evidence suggests that a dose of 175 mg/m2 administered over 3 hours is the optimal regimen for single-agent paclitaxel.
  • Weekly moderate-dose paclitaxel administration is gaining attention as a dose-dense chemotherapy approach.
  • This weekly schedule is associated with very modest myelosuppression, indicating a favorable toxicity profile.

Impact:

  • Provides guidance for clinicians on the current recommended paclitaxel dosing and infusion schedule.
  • Highlights the potential of weekly, dose-dense paclitaxel therapy for improved patient outcomes.
  • Suggests that further research into weekly paclitaxel may lead to refined treatment strategies with reduced side effects.

Related Experiment Videos